Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QLS 4131

Next Previous
Drug Profile

QLS 4131

Alternative Names: QLS-4131

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 03 Jun 2025 Qilu Pharmaceutical plans to initiate a phase I trial for Systemic Lupus Erythematosus (Treatment experienced) (Parenteral) (NCT07001839)
  • 25 Apr 2025 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Recurrent) in China (Parenteral) prior to April 2025 (NCT06500507)
  • 25 Apr 2025 Adverse events, pharmacokinetic and pharmacodynamics data from a preclinical studies in Multiple myeloma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top